Vegter Stefan, Boersma Cornelis, Rozenbaum Mark, Wilffert Bob, Navis Gerjan, Postma Maarten J
Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands.
Pharmacoeconomics. 2008;26(7):569-87. doi: 10.2165/00019053-200826070-00005.
The fields of pharmacogenetics and pharmacogenomics have become important practical tools to progress goals in medical and pharmaceutical research and development. As more screening tests are being developed, with some already used in clinical practice, consideration of cost-effectiveness implications is important. A systematic review was performed on the content of and adherence to pharmacoeconomic guidelines of recent pharmacoeconomic analyses performed in the field of pharmacogenetics and pharmacogenomics. Economic analyses of screening strategies for genetic variations, which were evidence-based and assumed to be associated with drug efficacy or safety, were included in the review. The 20 papers included cover a variety of healthcare issues, including screening tests on several cytochrome P450 (CYP) enzyme genes, thiopurine S-methyltransferase (TMPT) and angiotensin-converting enzyme (ACE) insertion deletion (ACE I/D) polymorphisms. Most economic analyses reported that genetic screening was cost effective and often even clearly dominated existing non-screening strategies. However, we found a lack of standardization regarding aspects such as the perspective of the analysis, factors included in the sensitivity analysis and the applied discount rates. In particular, an important limitation of several studies related to the failure to provide a sufficient evidence-based rationale for an association between genotype and phenotype. Future economic analyses should be conducted utilizing correct methods, with adherence to guidelines and including extensive sensitivity analyses. Most importantly, genetic screening strategies should be based on good evidence-based rationales. For these goals, we provide a list of recommendations for good pharmacoeconomic practice deemed useful in the fields of pharmacogenetics and pharmacogenomics, regardless of country and origin of the economic analysis.
药物遗传学和药物基因组学领域已成为推动医学和制药研发目标实现的重要实用工具。随着越来越多的筛查测试被开发出来,其中一些已应用于临床实践,考虑成本效益影响至关重要。对药物遗传学和药物基因组学领域近期进行的药物经济学分析的药物经济学指南内容及遵循情况进行了系统综述。该综述纳入了基于证据且假定与药物疗效或安全性相关的基因变异筛查策略的经济学分析。纳入的20篇论文涵盖了各种医疗保健问题,包括对几种细胞色素P450(CYP)酶基因、硫嘌呤甲基转移酶(TMPT)和血管紧张素转换酶(ACE)插入缺失(ACE I/D)多态性的筛查测试。大多数经济学分析报告称,基因筛查具有成本效益,而且往往甚至明显优于现有的非筛查策略。然而,我们发现,在分析视角、敏感性分析中纳入的因素以及应用的贴现率等方面缺乏标准化。特别是,几项研究的一个重要局限性在于未能为基因型与表型之间的关联提供充分的循证依据。未来的经济学分析应采用正确的方法进行,遵循指南并进行广泛的敏感性分析。最重要的是,基因筛查策略应基于充分的循证依据。为实现这些目标,我们提供了一份良好药物经济学实践的建议清单,这些建议在药物遗传学和药物基因组学领域被认为是有用的,无论经济分析的国家和来源如何。